Chronic Lung Disease Respiratory Chronic Lung Disease
Conditions
Interventions
This is a non-randomised feasibility study. Patients who fulfill the inclusion criteria will be invited to take part in a pulmonary rehabilitation programme (intervention) twice a week for six weeks,
step ups
cycling and walking
2. Equipment – minimal for exercise so can be continued at home (e.g. weights are bottles filled with water)
3. Regime individually prescribed, moni
Sponsors
Plymouth University, Peninsula Schools of Medicine and Dentistry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or over 2. Diagnosis of chronic obstructive pulmonary disease (COPD) or tuberculosis (TB) 3. Seen at Mulago Hospital as an inpatient or outpatient 4. Medical Research Council dyspnoea score grade 2 (MRC2) or higher 5. No unstable cardiovascular disease or locomotor difficulties that preclude exercise
Exclusion criteria
Exclusion criteria: 1. Smear positive TB for those with previous TB treatment 2. Unwilling or unable to attend a PR programme 3. Unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility and acceptability of pulmonary rehabilitation programme is determined at baseline, 6 weeks (end of intervention) and 12 weeks (6 weeks after intervention completion) using the following measures: 1. Walking distance measured using the Incremental Shuttle Walking Test 2. Quality of life measured using the disease specific Clinical COPD and EQ-5D questionnaires 3. Breathlessness measured using the MRC Dyspnoea Scale, Spirometry, Oximetry and Biometrics 4. Functional ability measured using the Karnofsky Scale, Borg Score and sit to stand time 5. Participant experience measured using ethnographic observations, individual interviews and focus groups at baseline, during the pulmonary rehabilitation intervention and 12 weeks (6 weeks after intervention completion) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Chest pain is measured using a subset of questions from the Brief Pain Inventory at baseline, 6 weeks (end of intervention) and 12 weeks (6 weeks after intervention completion) 2. Haemoptysis is measured using a single question rating scale at baseline, 6 weeks (end of intervention) and 12 weeks (6 weeks after intervention completion) 3. Depression is measured using the PHQ-9 all measured at baseline, 6 weeks (end of intervention) and 12 weeks (6 weeks after intervention completion) | — |
Countries
Uganda
Outcome results
None listed